trending Market Intelligence /marketintelligence/en/news-insights/trending/UGx74j4746v2i-UgH4Devg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

PDL BioPharma raises common stock, note repurchase authorization to $275M

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


PDL BioPharma raises common stock, note repurchase authorization to $275M

PDL BioPharma Inc.'s board has authorized the repurchase of up to $275 million of common stock and convertible notes, an increase of $75 million from the prior authorization.

PDL, which acquires, manages, and commercializes commercial-stage pharmaceutical assets and late-clinical-stage pharmaceutical products, initially authorized $200 million for the buyback of shares and notes.

On Dec. 13, the company said it had entered a private agreement to exchange 80% of its outstanding 2.75% convertible senior notes due Dec. 2021 and Dec. 2024 for $98 million in cash and 13.4 million of its common shares.

The cash and common stock to be distributed by PDL in this exchange will utilize about $143.8 million of the original $200 million authorization.